

ONCOLOGY CLINICAL NOTE

Patient Name: Mary Johnson

Date of Birth: July 22, 1958 (Age: 67)

Date of Note: November 18, 2025

Diagnosis: Malignant neoplasm of unspecified site of unspecified female breast (ICD-10: C50.919)

HISTORY OF PRESENT ILLNESS

Ms. Johnson is a 67-year-old female with a diagnosis of breast cancer (C50.919). She has a history of prior intervention including surgery and/or chemotherapy. She presents today for therapeutic planning following recent immunohistochemical (IHC) analysis.

LABORATORY & BIOMARKER RESULTS

Tissue analysis for Human Epidermal Growth Factor Receptor 2 (HER2) status was performed. The results are summarized below:

Biomarker / Test	Result	Clinical Interpretation
HER2 IHC	3+ (Positive)	Overexpression of HER2 protein detected. Patient is a candidate for HER2-targeted therapy (e.g., trastuzumab).

ASSESSMENT

The patient has HER2-positive breast cancer (IHC 3+). Given the overexpression of HER2, she requires targeted anti-HER2 therapy to improve disease-free and overall survival outcomes.

TREATMENT PLAN

1. Pharmacotherapy

- Initiate Trastuzumab:** Administer as targeted therapy for HER2-positive disease.
- Dosing:** Loading dose followed by maintenance dosing per standard weight-based protocol.

2. Monitoring & Follow-up

- Cardiac Monitoring:** Obtain baseline Echocardiogram or MUGA scan prior to initiation. Repeat cardiac monitoring every 3 months during treatment to assess Left Ventricular

Ejection Fraction (LVEF), as per trastuzumab safety protocols.

- Monitor for infusion-related reactions.

3. Administrative & Coverage

- **Insurance Provider:** Aetna
- **Policy Number:** INS67890
- **Status:** Active (Coverage verified Jan 2025 – Dec 2025)
- **Action:** Verify authorization requirements for biologic therapy.

Electronically Signed By:

[Provider Name, MD/DO]

Department of Oncology